Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRL-201 CAR-T in relapsed/refractory B-cell NHL
NCT05741359Phase 1Recruiting
- Sponsor
- BRL Medicine Inc.
- Start
- Apr 2023
- Primary completion
- Nov 2026
- Modality
- Gene Silencing, CRISPR-Cas9, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BRL-201 in B-cell non-Hodgkin lymphoma (4 arms), sponsored by BRL Medicine Inc. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 24 months and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
BRL-201
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05741359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05741359.